6533b826fe1ef96bd128483e

RESEARCH PRODUCT

Nonmedical use of prescription drugs in the European Union

Jose Martinez-ragaKarol KrotkiAnders HåkanssonJens ReimerScott P. NovakSajan Varughese

subject

AdultMalemedicine.medical_specialtyPrescription drugPrescription DrugsCross-sectional studySubstance-Related Disordersmedicine.medical_treatmentDenmarkPopulationPharmacyThinking03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsGermanymedicinePrevalencemedia_common.cataloged_instanceHypnotics and SedativesHumans030212 general & internal medicineEuropean UnionEuropean unionMedical prescriptionPsychiatryeducationPrescription Drug MisuseReproductive healthmedia_commonSwedeneducation.field_of_studybusiness.industryUnited KingdomStimulantAnalgesics OpioidEuropePsychiatry and Mental healthCross-Sectional StudiesSpainCentral Nervous System StimulantsFemalebusiness030217 neurology & neurosurgeryResearch Article

description

Background Nonmedical prescription drug use (NMPDU) refers to the self-treatment of a medical condition using medication without a prescriber’s authorization as well as use to achieve euphoric states. This article reports data from a cross-national investigation of NMPDU in five European Countries, with the aim to understand the prevalence and characteristics of those engaging in NMPDU across the EU. Methods A parallel series of self-administered, cross-sectional, general population surveys were conducted in 2014. Data were collected using multi-stage quota sampling and then weighted using General Exponential Model. A total of 22,070 non-institutionalized participants, aged 12 to 49 years, in 5 countries: Denmark, Germany, Great Britain, Spain, and Sweden. Lifetime and past-year nonmedical use of prescription medications such as stimulants, opioids, and sedatives were ascertained via a modified version of the World Health Organization’s Composite International Diagnostic Interview. Information about how the medications were acquired for NMPDU were also collected from the respondent. Results Lifetime and past-year prevalence of nonmedical prescription drug use was estimated for opioids (13.5 and 5.0 %), sedatives (10.9 and 5.8 %), and stimulants (7.0 and 2.8 %). Germany exhibited the lowest levels of NMPDU, with Great Britain, Spain, and Sweden having the highest levels. Mental and sexual health risk factors were associated with an increased likelihood of past-year nonmedical prescription drug use. Among past-year users, about 32, 28, and 52 % of opioid, sedative, and stimulant nonmedical users, respectively, also consumed illicit drugs. Social sources (sharing by friends/family) were the most commonly endorsed methods of acquisition, ranging from 44 % (opioids) to 62 % (sedatives). Of interest is that Internet pharmacies were a common source of medications for opioids (4.1 %), stimulants (7.6 %), and sedatives (2.7 %). Conclusions Nonmedical prescription drug use was reported across the five EU countries we studied, with opioids and sedatives being the most prevalent classes of prescription psychotherapeutics. International collaborations are needed for continued monitoring and intervention efforts to target population subgroups at greatest risk for NMDU.

10.1186/s12888-016-0909-3http://europepmc.org/articles/PMC4972971